Tests a brain stimulation device for negative symptoms and thinking problems in schizophrenia
Tests weak electrical brain stimulation in adults with schizophrenia who have long been hospitalized.
Plain-language title generated from the registry record
Registry title: tACS to Improve Negative Symptoms & Cognition in Long-term Hospitalized Schizophrenia Patients.
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07074704, who can take part
Where in China
- Shanghai Pudong New Area Mental Health CenterShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tongji University
- Trial code
- NCT07074704
- Record updated
- 24 July 2025
- Original description
This study aims to evaluate the efficacy of transcranial alternating current stimulation (tACS) on negative symptoms and cognitive function in long-term hospitalized patients with schizophrenia. At the same time, this study will explore the potential impact of relevant biomarkers and genetic factors on the efficacy of tACS intervention.Read full original descriptionShow less
Transcranial Alternating Current Stimulation (tACS) as an Augmentation Treatment for Negative Symptoms and Cognitive Deficits in Long-term Hospitalized Schizophrenia Patients
This study aims to evaluate the efficacy of transcranial alternating current stimulation (tACS) on negative symptoms and cognitive function in long-term hospitalized patients with schizophrenia. At the same time, this study will explore the potential impact of relevant biomarkers and genetic factors on the efficacy of tACS intervention.
Inclusion: Inclusion criteria for long-term hospitalized schizophrenia patients:; Diagnosed with DSM-5 schizophrenia and hospitalized for more than half a year; Aged between 18 and 65 years old; Willing to participate in the study and sign the informed consent; Stable condition, PANSS total score changed less than 15% at least 2 months before the study; Education level above primary school; Normal vision or normal after correction; No diagnosed mental illness; Aged between 18 and 65 years old; Willing to participate in the study and sign the informed consent; Education level above primary school; Normal vision or normal after correction; Residents living in Pudong community.
Exclusion: Use of other drugs that affect the results during the study, such as benzodiazepines, non-benzodiazepine sedatives, and psychostimulants; Patients with alcohol, drugs Abuse history; Patients who have received TACS treatment in the past and have no effect or intolerance; During the study, drugs that affect the results were used in combination, such as benzodiazepines, non-benzodiazepine sedatives, and psychostimulants; Combined diagnosis of other mental illnesses in DSM-5; History of severe neurological diseases, epilepsy, craniocerebral trauma, etc; Severe organic diseases of the heart, liver, kidney and other organs that are unstable; Infectious skin diseases; Patients with a history of severe neurological diseases, epilepsy, craniocerebral trauma, etc; Patients with severe organic diseases that cause instability of organs such as heart, liver, and kidney; Patients with infectious skin diseases; Patients with a history of alcohol and drug abuse -; Pregnant or lactating women; Patients with claustrophobia; Pregnant or lactating women; Patients with claustrophobia.